Skip to main content

Allogene Therapeutics, Inc.

ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001737287

In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Allogene Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $63.0K in total
Insiders trading
1
Net value
−$63.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Allogene Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Allogene Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Douglas Earl MartinSVP, General Counsel488,267Aug 25, 20262
Roberts ZacharyPresident and CEO581,166Jul 6, 20263
Sato Vicki LDirector162,575Jun 23, 20261
Kazam Joshua ADirector398,463Jun 23, 20262
Humer Franz BDirector307,507Jun 23, 20261
Witte Owen N.Director292,832Jun 23, 20261
Messemer Deborah M.Director107,431Jun 23, 20261
Barrett Elizabeth A.Director–Jun 23, 20261
Mayo StephenDirector25,328Jun 23, 20261
Yoshiyama AnnieSVP, Finance124,517Apr 23, 20262
Beneski Benjamin MachinasSVP, Chief Technical Officer195,338Apr 2, 20265
Chang David DPresident and CEO5,150,599Mar 18, 20262
Belldegrun ArieDirector2,236,816Feb 4, 20261
Parker Geoffrey M.CHIEF FINANCIAL OFFICER1,252,795Feb 4, 20262
Moore Timothy L.Chief Technical Officer250,713Feb 5, 20250
Chen Yinlin JackSVP, Finance88,881Aug 14, 20230
Smith LillianVP, Corporate Counsel140,390Apr 5, 20230
Schmidt Eric ThomasChief Financial Officer862,439Mar 24, 20230
Moore AlisonChief Technical Officer672,731Mar 24, 20230
Bhavnagri VeerGeneral Counsel556,049Mar 16, 20230
Amado RafaelEVP of R&D541,946Oct 11, 20220
PF Equity Holdings 2 B.V.10% Owner0Apr 4, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 25, 2026 (view filing)4:43 PM ETAug 214 daysDouglas Earl MartinSVP, General CounselSSale−29.7K$2.12−$63.0K−5.7%488.3K after
Apr 23, 2026 (view filing)Apr 212 daysYoshiyama AnnieSVP, FinanceSSale−9.59K$2.31−$22.1K−7.1%124.5K after
Apr 2, 2026 (view filing)Mar 312 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−2.87K$2.50−$7.17K−1.4%195.3K after
Mar 18, 2026 (view filing)Mar 162 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−4.83K$2.47−$11.9K−2.4%198.2K after
Mar 18, 2026 (view filing)Mar 162 daysChang David DPresident and CEOSSale−47.8K$2.47−$118.0K−0.9%5.15M after
Mar 4, 2026 (view filing)Mar 22 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−7.13K$2.60−$18.5K−3.4%203.0K after
Feb 4, 2026 (view filing)Feb 22 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−7.55K$1.73−$13.1K−3.5%210.2K after
Feb 4, 2026 (view filing)Feb 22 daysChang David DPresident and CEOSSale−95.3K$1.80−$171.5K−1.8%5.19M after
Feb 4, 2026 (view filing)Feb 22 daysParker Geoffrey M.CHIEF FINANCIAL OFFICERSSale−24.0K$1.76−$42.2K−1.9%1.25M after
Feb 4, 2026 (view filing)Feb 22 daysYoshiyama AnnieSVP, FinanceSSale−4.17K$1.72−$7.17K−3.1%130.3K after
Feb 4, 2026 (view filing)Feb 22 daysRoberts ZacharyEVP of R&DSSale−35.7K$1.77−$63.2K−5.8%581.2K after
Feb 4, 2026 (view filing)Feb 22 daysDouglas Earl MartinSVP, General CounselSSale−22.9K$1.76−$40.3K−3.9%564.9K after
Jan 23, 2026 (view filing)Jan 212 daysRoberts ZacharyEVP of R&DSSale−26.3K$1.56−$41.0K−4.1%616.9K after
Nov 19, 2025 (view filing)Nov 172 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−786$1.22−$958.92−0.4%217.7K after
Oct 23, 2025 (view filing)Oct 212 daysParker Geoffrey M.CHIEF FINANCIAL OFFICERSSale−36.7K$1.26−$46.3K−2.8%1.28M after
Jun 12, 2025 (view filing)Jun 102 daysMessemer Deborah M.DirectorSSale−36.9K$1.42−$52.4K−25.6%107.4K after10b5-1
Apr 23, 2025 (view filing)Apr 212 daysYoshiyama AnnieSVP, FinanceSSale−9.60K$1.41−$13.5K−6.8%130.7K after
Mar 18, 2025 (view filing)Mar 144 daysChang David DPresident and CEOSSale−46.7K$1.96−$91.5K−0.9%5.28M after
Mar 18, 2025 (view filing)Mar 144 daysBeneski Benjamin MachinasSVP, Chief Technical OfficerSSale−5.49K$1.98−$10.9K−2.5%218.5K after
Feb 20, 2025 (view filing)Feb 182 daysMessemer Deborah M.DirectorSSale−13.3K$2.43−$32.4K−8.4%144.3K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysDouglas Earl MartinSVP, General CounselSSale−6.40K$1.71−$11.0K−1.1%587.8K after
Feb 5, 2025 (view filing)Feb 32 daysParker Geoffrey M.CHIEF FINANCIAL OFFICERSSale−4.36K$1.73−$7.54K−0.3%1.30M after
Feb 5, 2025 (view filing)Feb 32 daysMoore Timothy L.Chief Technical OfficerSSale−14.7K$1.71−$25.2K−5.6%250.7K after
Feb 5, 2025 (view filing)Feb 32 daysChang David DPresident and CEOSSale−46.0K$1.68−$77.3K−0.9%5.32M after
Feb 5, 2025 (view filing)Feb 32 daysRoberts ZacharyEVP of R&DSSale−18.8K$1.70−$32.0K−2.8%643.1K after
Jan 23, 2025 (view filing)Jan 212 daysRoberts ZacharyEVP of R&DSSale−27.2K$1.78−$48.4K−5.3%488.1K after
Dec 10, 2024 (view filing)Dec 91 dayMessemer Deborah M.DirectorSSale−9.14K$2.18−$19.9K−5.5%157.6K after10b5-1
Dec 9, 2024 (view filing)Dec 54 daysHumer Franz BDirectorSSale−9.22K$2.16−$19.9K−2.9%307.5K after
Jun 20, 2024 (view filing)Jun 182 daysMessemer Deborah M.DirectorSSale−18.6K$2.28−$42.5K−10.1%166.8K after10b5-1
Jun 3, 2024 (view filing)May 304 daysHumer Franz BDirectorSSale−11.2K$2.34−$26.2K−4.2%255.3K after
May 20, 2024 (view filing)May 164 daysBelldegrun ArieDirectorPPurchase+1.72M$2.90+$5.00MNew position1.72M after
Mar 6, 2024 (view filing)Jan 3036 daysLateParker Geoffrey M.CHIEF FINANCIAL OFFICERPPurchase+190$3.60+$6840.0%819.6K after
Dec 20, 2023 (view filing)Dec 182 daysMessemer Deborah M.DirectorSSale−18.6K$2.70−$50.3K−23.0%62.5K after10b5-1
Aug 9, 2023 (view filing)Aug 72 daysMayo StephenDirectorSSale−10.0K$4.29−$42.9K−28.3%25.3K after
Feb 14, 2023 (view filing)Feb 131 dayBhavnagri VeerGeneral CounselSSale−3.00K$6.85−$20.6K−0.5%577.7K after
Jan 18, 2023 (view filing)Jan 171 dayBhavnagri VeerGeneral CounselSSale−3.00K$7.04−$21.1K−0.5%580.7K after
Dec 19, 2022 (view filing)Dec 154 daysBhavnagri VeerGeneral CounselSSale−5.60K$7.53−$42.2K−1.0%583.7K after
Aug 15, 2022 (view filing)Aug 11-124 daysWitte Owen N.DirectorSSale−15.0K$16.75−$251.3K−6.4%218.3K after2 lotsDuplicate filing
Aug 15, 2022 (view filing)Aug 11-124 daysWitte Owen N.DirectorSSale−15.0K$16.75−$251.3K−6.4%218.3K after2 lots
Aug 2, 2022 (view filing)Aug 2Same dayAmado RafaelEVP of R&D and CMOSSale−2.00K$11.97−$23.9K−0.4%540.3K after
Jul 6, 2022 (view filing)Jul 51 dayAmado RafaelEVP of R&D and CMOSSale−2.00K$11.44−$22.9K−0.4%542.3K after
Jun 23, 2022 (view filing)Jun 221 dayWitte Owen N.DirectorSSale−10.0K$11.76−$117.6K−4.1%233.3K after
Jun 22, 2022 (view filing)Jun 211 dayAmado RafaelEVP of R&D and CMOSSale−2.00K$11.18−$22.4K−0.4%544.3K after
May 19, 2022 (view filing)May 19Same dayAmado RafaelEVP of R&D and CMOSSale−11.5K$7.40−$85.1K−2.1%546.3K after
Mar 17, 2022 (view filing)Mar 152 daysAmado RafaelEVP of R&D and CMOSSale−5.17K$7.71−$39.9K−1.6%320.1K after
Mar 17, 2022 (view filing)Mar 152 daysBhavnagri VeerGeneral CounselSSale−8.85K$7.68−$68.0K−2.1%413.8K after
Mar 17, 2022 (view filing)Mar 152 daysChang David DPresident and CEOSSale−23.6K$7.65−$180.9K−1.0%2.29M after
Mar 17, 2022 (view filing)Mar 152 daysSchmidt Eric ThomasChief Financial OfficerSSale−11.5K$7.63−$87.5K−10.2%100.5K after
Mar 17, 2022 (view filing)Mar 152 daysMoore AlisonChief Technical OfficerSSale−8.70K$7.63−$66.4K−6.7%120.4K after
Jan 14, 2022 (view filing)Jan 122 daysKazam Joshua ADirectorPPurchase+15.0K$12.60+$189.0K+6.2%258.9K after